DZ964A1 - Procédé d'obtention de formes pharmaceutiques solides à liberation prolongée. - Google Patents

Procédé d'obtention de formes pharmaceutiques solides à liberation prolongée.

Info

Publication number
DZ964A1
DZ964A1 DZ860158A DZ860158A DZ964A1 DZ 964 A1 DZ964 A1 DZ 964A1 DZ 860158 A DZ860158 A DZ 860158A DZ 860158 A DZ860158 A DZ 860158A DZ 964 A1 DZ964 A1 DZ 964A1
Authority
DZ
Algeria
Prior art keywords
sustained
release pharmaceutical
pharmaceutical forms
drug
obtaining solid
Prior art date
Application number
DZ860158A
Other languages
English (en)
Inventor
Rosa Martani
Le Elisabeth Huede
Jeanne Dumas
Original Assignee
Cortial
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortial filed Critical Cortial
Application granted granted Critical
Publication of DZ964A1 publication Critical patent/DZ964A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
DZ860158A 1985-07-26 1986-07-23 Procédé d'obtention de formes pharmaceutiques solides à liberation prolongée. DZ964A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8511575A FR2585246A1 (fr) 1985-07-26 1985-07-26 Procede d'obtention de formes pharmaceutiques solides a liberation prolongee

Publications (1)

Publication Number Publication Date
DZ964A1 true DZ964A1 (fr) 2004-09-13

Family

ID=9321740

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ860158A DZ964A1 (fr) 1985-07-26 1986-07-23 Procédé d'obtention de formes pharmaceutiques solides à liberation prolongée.

Country Status (13)

Country Link
US (1) US4834965A (fr)
EP (1) EP0214735B1 (fr)
AT (1) ATE66599T1 (fr)
AU (1) AU585377B2 (fr)
CA (1) CA1304684C (fr)
DE (1) DE3681099D1 (fr)
DZ (1) DZ964A1 (fr)
ES (1) ES2000555A6 (fr)
FR (1) FR2585246A1 (fr)
MA (1) MA20745A1 (fr)
OA (1) OA08368A (fr)
PT (1) PT83052B (fr)
ZA (1) ZA865455B (fr)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0249347B1 (fr) * 1986-06-10 1994-06-29 Euroceltique S.A. Composition à libération contrôlée de dihydrocodéine
NZ226575A (en) * 1987-10-16 1991-01-29 Elan Corp Plc Controlled release formulation containing cis-(+)-3-acetyloxy-5-(2-(dimethylamino)ethyl)-2,3 dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepine-4(5h)one(diltiazem) and having a surrounding membrane
EP0406315B1 (fr) * 1988-03-24 1992-11-11 Bukh Meditec A/S Composition a diffusion regulee
FR2630913A1 (fr) * 1988-05-09 1989-11-10 Delalande Sa Comprimes de sel(s) hydrosoluble(s) de diltiazem a liberation programmee et leur procede de fabrication
IE60726B1 (en) * 1988-09-20 1994-08-10 Glaxo Group Ltd Pharmaceutical compositions
JP3623805B2 (ja) * 1992-02-20 2005-02-23 ユーロセルテイツク・エス・アー ヒドロモルホンスフェロイド調整放出製剤
GB9203689D0 (en) * 1992-02-20 1992-04-08 Euro Celtique Sa Pharmaceutical composition
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
USRE39300E1 (en) 1993-01-28 2006-09-19 Virginia Commonwealth University Medical College Of Virginia Inhibiting the development of tolerance to and/or dependence on an addictive substance
DE4319649A1 (de) * 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
IL119660A (en) 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US5932248A (en) * 1993-11-18 1999-08-03 Paragon Medical Limited Controlled release preparations for cytotoxic or cytostatic drugs
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
US6063370A (en) * 1996-04-05 2000-05-16 The Board Of Trustees Of The University Of Illinois Macromolecular complexes for drug delivery
US6057367A (en) * 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
US5935599A (en) * 1996-10-28 1999-08-10 The Board Of Trustees Of The University Of Illinois Polymer-associated liposomes for drug delivery and method of manufacturing the same
HUP0100310A3 (en) * 1997-12-22 2002-11-28 Euro Celtique Sa A method of preventing abuse of opioid dosage forms
EP2266564B1 (fr) * 1997-12-22 2013-03-13 Euro-Celtique S.A. Formulation pharmaceutique pour administration orale comprenant en combinaison un agoniste et un antagoniste des récepteurs opiacés
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
ES2540103T3 (es) 2000-02-08 2015-07-08 Euro-Celtique S.A. Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6417237B1 (en) * 2000-06-08 2002-07-09 The Board Of Trustees Of The University Of Illinois Macromolecular drug complexes and compositions containing the same
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
US6855721B1 (en) 2000-07-28 2005-02-15 Indevus Pharmaceuticals, Inc. Methods and compositions for alleviating stuttering
WO2002092060A1 (fr) 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Forme posologique d'opioides a liberation prolongee empechant la consommation abusive
DK1416842T3 (da) * 2001-07-18 2009-03-16 Euro Celtique Sa Farmaceutiske kombinationer af oxycodon og naloxon
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
ES2326794T3 (es) 2001-08-06 2009-10-20 Euro-Celtique S.A. Formulaciones de agonistas opioides con antagonista liberable y secuestrado.
ES2608006T3 (es) 2002-04-05 2017-04-05 Euro-Celtique S.A. Preparación farmacéutica que contiene oxicodona y naloxona
US20050020613A1 (en) * 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
AU2003270778B2 (en) * 2002-09-20 2009-10-08 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
US20050137265A1 (en) * 2003-03-31 2005-06-23 Haley Eugene T. Rapidly dissolving metoclopramide solid oral dosage and method thereof
US20040192781A1 (en) * 2003-03-31 2004-09-30 Haley Eugene T. Method of administration for metoclopramide and pharmaceutical formulation therefor
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
US8906413B2 (en) 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
CA2547847A1 (fr) * 2003-12-18 2005-07-07 Huntsman Petrochemical Corporation Granules pesticides a liberation rapide ameliores en tensioactif
CA2564731A1 (fr) 2004-04-27 2005-11-10 Medicinova, Inc. Derives d'acide phenoxyalkycarboxylique pour le traitement des maladies inflammatoires
EP1750710B1 (fr) * 2004-05-14 2014-04-16 KNU-Industry Cooperation Foundation Proprietes neuroprotectrices de morphinanes de dextrorotation
EP1604666A1 (fr) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioides pour le traitement de la bronchopneumopathie chronique obstructive
WO2006044805A2 (fr) * 2004-10-15 2006-04-27 Supernus Pharmaceuticals, Inc. Preparations pharmaceutiques pour lesquelles le risque d'abus est reduit
EP1702558A1 (fr) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Procédé et dispositif pour évaluer la fonction de l'activité intestinale
US20060263427A1 (en) * 2005-05-03 2006-11-23 Roberts Richard H Quinine formulations
CN101299993A (zh) * 2005-11-04 2008-11-05 伊士曼化工公司 用于给药难溶的药学活性剂的羧烷基纤维素酯
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
DK2526932T3 (en) * 2006-06-19 2017-07-17 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
PT2317991T (pt) * 2008-07-07 2017-08-03 Euro Celtique Sa Utilização de antagonistas de opióides para tratar a retenção urinária
WO2010078486A2 (fr) * 2008-12-31 2010-07-08 Upsher-Smith Laboratories, Inc. Compositions pharmaceutiques orales contenant un opioïde et procédés
US11304960B2 (en) * 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
AR075735A1 (es) 2009-03-10 2011-04-20 Euro Celtique Sa Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
CA2773521C (fr) 2009-09-17 2017-01-24 Upsher-Smith Laboratories, Inc. Produit a liberation prolongee comprenant une combinaison d'une amine non opioide et d'un medicament anti-inflammatoire non steroidal
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US8962687B2 (en) 2012-12-05 2015-02-24 Medicinova, Inc. Method of treating liver disorders
US8835499B2 (en) 2011-12-08 2014-09-16 Medicinova, Inc. Method of treating non-alcoholic fatty liver disease and steatohepatitis
JP2016525138A (ja) 2013-07-23 2016-08-22 ユーロ−セルティーク エス．エイ． 疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
US20150031769A1 (en) 2013-07-25 2015-01-29 Medicinova, Inc. Methods for reducing triglyceride, total cholesterol and low density lipoprotein blood levels
EP3079668A1 (fr) 2013-12-09 2016-10-19 Durect Corporation Complexes de principes pharmaceutiquement actifs, complexes de polymères, et compositions et procédés les impliquant
US9346754B2 (en) 2014-05-08 2016-05-24 Medicinova, Inc. Method of treating advanced non-alcoholic steatohepatitis
US20150321989A1 (en) 2014-05-08 2015-11-12 Medicinova, Inc. Method of treating idiopathic pulmonary fibrosis
CN106470678A (zh) 2014-06-02 2017-03-01 美迪诺亚公司 抑制或治疗纤维化的方法
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (fr) 2014-08-28 2016-03-03 Lipocine Inc. Esters de (17-β)-hydroxy-4-androstène-3-one biodisponibles à l'état solide
GB201506755D0 (en) 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
BR112017010700A2 (pt) 2014-11-26 2018-05-08 Medicinova Inc combinação de ibudilaste e riluzol e métodos de uso da mesma
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
WO2017062997A1 (fr) 2015-10-09 2017-04-13 Reckitt Benckiser Llc Formulation pharmaceutique
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
JP2021531348A (ja) 2018-07-20 2021-11-18 リポシン，インク． 肝臓病
CA3217719A1 (fr) 2021-05-28 2022-12-01 Kazuko Matsuda Derives d'acide phenoxyalkylcarboxylique et leur utilisation pour abaisser les taux de triglycerides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2802114A1 (de) * 1978-01-19 1979-07-26 Sandoz Ag Neue pharmazeutische zusammensetzung und verfahren zu deren herstellung
FR2523446A1 (fr) * 1982-03-19 1983-09-23 Dietlin Francois Nouveau procede d'obtention de formes pharmaceutiques a liberation programmee
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
US4795327A (en) * 1984-03-26 1989-01-03 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
US4624848A (en) * 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4892742A (en) * 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release

Also Published As

Publication number Publication date
AU6058386A (en) 1987-01-29
ATE66599T1 (de) 1991-09-15
PT83052A (en) 1986-08-01
CA1304684C (fr) 1992-07-07
US4834965A (en) 1989-05-30
MA20745A1 (fr) 1987-04-01
AU585377B2 (en) 1989-06-15
PT83052B (pt) 1988-07-01
EP0214735B1 (fr) 1991-08-28
ES2000555A6 (es) 1988-03-01
FR2585246A1 (fr) 1987-01-30
ZA865455B (en) 1987-03-25
EP0214735A1 (fr) 1987-03-18
DE3681099D1 (de) 1991-10-02
OA08368A (fr) 1988-02-29

Similar Documents

Publication Publication Date Title
DZ964A1 (fr) Procédé d'obtention de formes pharmaceutiques solides à liberation prolongée.
FR2599027B1 (fr) Derives de tetrahydronaphtalene et d'indane, utilisation pour la fabrication de preparations pharmaceutiques et procede d'obtention.
PT82610B (pt) Processo para a preparacao de tiazolidino-dionas hipoglicemicas
EP1026152A4 (fr) Procede de production de derives d'acide ethersulfonique de perfluorovinyle et copolymere correspondant
OA08871A (fr) Nouveaux dérivés de thiazole actif sur le système cholinergique, procédé d'obtention et compositions pharmaceutiques en contenant.
FR2629344B1 (fr) Preparation pharmaceutique a liberation controlee et procede pour sa production
DZ2786A1 (fr) Préparation pharmaceutique de sildénafil à délitement oral et procédé por sa production.
OA08192A (fr) Nouveau procédé d'obtention de formes pharmaceutiques à libération prolongée.
PT81091B (pt) Processo para a preparacao de comprimidos de libertacao constante
AT323719B (de) Verfahren zur herstellung von neuen n-hydroxyphenylalkyl-beta-(3,4-dihydroxyphenyl)-äthylaminen und deren pharmazeutisch annehmeaben mineralsäureadditionssalzen
EP0357565A3 (fr) Procédé de préparation de levodopa
EP0776873A3 (fr) Emulsion aqueuse d'alkylalkoxysilanes, procédé de sa préparation et son utilisation
PT92789A (pt) Processo para a preparacao de um polimero a base de cloreto de vinilo
IT8922135A0 (it) Processo per la produzione di soluzioni acquose di agenti anti-incrostazione e soluzioni cosi' ottenute
OA08689A (fr) Procédé de préparation de comprimés à dissolution et/ou délitement rapide et comprimés ainsi obtenus.
OA06469A (fr) Procédé d'obtention d'acides aminés à partir d'hydrolysats de protéines.
FR2627986B1 (fr) Composition pharmaceutique a base de 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1h-imidazol-1-yl)methyl)-4h-carbazol-4-one ou d'un de ses sels et de dexamethasone, son procede de preparation et ses utilisations
IT1165058B (it) Processo per la preparazione di polimeri graffati di alfa,alfa' disostituiti beta-propiolattoni su copolieri a base di isobutilene e trieni
DZ2757A1 (fr) Procédé pour la préparation d'acides hydroxamiques.
MA19021A1 (fr) Procede de preparation de compositions pharmaceutiques a base d'alpha-12-bis(i methyl ethyl)amino/alpha-phenyl 2-pyridine acetamide ou de l'un de ses sels
FR2709961B1 (fr) Forme pharmaceutique moulée pour administration orale à base d'acide acétylsalicylique ou de ses sels et son procédé de fabrication.
FR2583419B1 (fr) Procede pour la preparation de 2-bromo-a-ergocryptine et ses sels d'addition d'acides.
BR8900267A (pt) Processo para a preparacao de um polimero de acrilamida contendo grupos hidroxamicos
FR2708611B1 (fr) Sel de codéine de l'acide 2-(3-benzoylphényl)propionique, procédé d'obtention et compositions pharmaceutiques le contenant.
IT1203752B (it) Procedimento per la produzione di un supporto polimerico per reazioni topochimiche,supproto ottenuto e suo impiego